InnovAge (INNV) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Aug, 2026Executive summary
Fiscal Q3 2026 delivered a 15.5% year-over-year revenue increase to $251.9 million, with $61 million center-level contribution margin and $30.5 million adjusted EBITDA, serving about 8,050 participants across 20 centers in six states.
Year-to-date performance led to raised fiscal 2026 guidance for both revenue and adjusted EBITDA, reflecting improved operating execution and benefits from prior investments.
Investments in clinical teams, technology (including AI), and new centers, especially in Florida, are driving operational improvements and future growth.
Focus remains on quality, participant outcomes, and sustainable long-term performance, despite ongoing labor shortages, wage pressures, and regulatory challenges.
Ongoing legal and regulatory matters, including litigation and settlements, significantly impacted expenses and net loss.
Financial highlights
Total revenue for Q3 FY26 was $251.9 million, up 15.5% year-over-year and 5.1% sequentially, with nine-month revenue at $727.8 million, up 15.1%.
Center-level contribution margin rose to $61 million (24.2% of revenue), up from $40.7 million (18.7%) in Q3 FY25.
Adjusted EBITDA was $30.5 million (12.1% margin), up from $10.8 million (4.9%) in Q3 FY25; nine-month adjusted EBITDA was $70.3 million (9.7% margin).
Net loss widened to $29.9 million from $11.1 million in Q3 FY25, mainly due to increased litigation liability; net loss for nine months was $10.8 million.
Cash and equivalents at quarter-end were $95.5 million, with $43.1 million in short-term investments and $69.4 million in total debt.
Outlook and guidance
Fiscal 2026 revenue guidance raised to $950–$975 million and adjusted EBITDA to $85–$90 million.
Ending census expected between 7,900 and 8,100 participants; member months projected at 92,900–95,700.
De novo center losses for FY26 anticipated at $11.5–$13.5 million.
Fiscal 2027 expected to face more modest Medicare and Medicaid rate increases (Medicare 1.5–2%), creating top-line and margin pressure, especially in Colorado and California.
Plans to invest in operational initiatives, compliance, and participant growth and retention.
Latest events from InnovAge
- 2027 guidance targets $105–$115 million adjusted EBITDA, reflecting strong growth and margin expansion.INNV
Wells Fargo 21st Annual Healthcare Conference - Strong revenue and margin growth in 2026 set the stage for disciplined expansion in 2027.INNV
Q4 2026 - Q2 revenue and margins surged, driving a raised full-year outlook despite ongoing cost pressures.INNV
Q2 2026 - Revenue up 15.1%, net income positive, strong census growth, FY2026 guidance reaffirmed.INNV
Q1 2026 - Revenue up 11.8%, adjusted EBITDA doubled, and margin expanded; FY26 outlook remains strong.INNV
Q4 2025 - Revenue up 12.4%, net loss halved, and Adjusted EBITDA margin improved to 3.2%.INNV
Q1 2025 - Revenue up 11% to $764M, margins improved, FY25 guidance strong despite regulatory headwinds.INNV
Q4 2024 - Revenue up 13%, adjusted EBITDA rose to $10.8M, but net loss widened on higher costs.INNV
Q3 2025 - Revenue up 10.6% to $209M; FY2025 guidance reaffirmed amid margin and regulatory pressures.INNV
Q2 2025